Completed PHASE4 INTERVENTIONAL 3-arm NCT00118963

Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes

Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents

Sponsor: Steno Diabetes Center Copenhagen

Conditions Diabetes Mellitus, Type 2

Interventions Insulin BIAsp30 (Novolog 70/30) Metformin Placebo-Metformin Placebo-Repaglinide Repaglinide

Updated 7 times since 2017 Last updated: Dec 5, 2008 Started: Jan 31, 2003 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Steno Diabetes Center Copenhagen and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Steno Diabetes Center Copenhagen

Data source: Steno Diabetes Center Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gentofte Municipality, Denmark